What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at ...

Image of Cathie Wood via Wikimedia Commons. In a market dominated by headlines about artificial intelligence (AI), cloud ...

The market expects Illumina (ILMN) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...

According to the Adhishthana Principles, Illumina stock may remain under pressure for over 18 years — here's why.

Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target.

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Illumina (NASDAQ:ILMN – Free Report) had its target price trimmed by Canaccord Genuity Group from $92.00 to $87.00 in a report issued on Monday morning,Benzinga reports.

Illumina (NASDAQ:ILMN – Get Free Report) had its price target dropped by Morgan Stanley from $136.00 to $100.00 in a research report issued on Monday,Benzinga reports. The firm currently has an ...

In a report released today, Daniel Brennan from TD Cowen maintained a Hold rating on Illumina, with a price target of $106.00. The company’s shares closed today at $96.94. Eleva ...

Illumina (NASDAQ:ILMN) stock dips as Scotiabank downgrades. However, peers Danaher (DHR) stock and Thermo Fisher ... raising the stock’s target price to $275 from $265 per share.